MedTrace Logo

Influence of Systemic Parameters in Diabetic Macular Edema - LIPSIA Study

NCT03762226 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2018-12-03

No results posted yet for this study

Summary

This study aims to evaluate the influence and prognostic value of systemic factors (such as the cardiovascular and metabolic status) on the treatment response to anti-VEGF therapy in macular edema due to diabetes or retinal vein occlusion.

Conditions

Interventions

DRUG

Anti-VEGF

Patients will undergo as part of the routine care 4 monthly anti-VEGF injections.

Sponsors & Collaborators

  • University of Leipzig

    lead OTHER

Principal Investigators

  • Matus Rehak, MD, PhD · University Hospital Leipzig, Department of Ophthalmology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2021-06-30
Completion
2021-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03762226 on ClinicalTrials.gov